Jonah Lupton - Why peptides are so bullish for Hims & Hers

Apr 17, 2026 · 0:58:39

Listen to Episode

✨ AI Summary

Jonah Lupton presents his bullish case for Hims & Hers, focusing on peptides.
He argues peptides, GLPs, and testosterone are key to his thesis.
Lupton discusses the upcoming FDA advisory meeting on peptides.

Guests on This Episode

JL

Jonah Lupton

1 podcast appearance

More from Hims House

Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027

Aug 7, 2026 · 0:54:27

🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem

Jul 27, 2026 · 0:59:34

The FDA peptides vote is days away. This insider expects approval

Jul 15, 2026 · 1:01:14

Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share

Jul 7, 2026 · 1:00:30

View all episodes →